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1. Introduction 
Prostate cancer is diagnosed in over 230,000 men each year in the United States (Jemel, et al, 
2006), and with the use of screening prostate specific antigen (PSA) the majority is 
diagnosed with locally confined prostate cancer. Many of these patients are good candidates 
for prostate brachytherapy. With the development of transperineal implantation using 
trans-rectal ultrasound guidance the number of patients undergoing permanent radioactive 
seed implants for prostate cancer has increased significantly over the past ten years. 
(Cooperberg, et al, 2004). 
A variety of techniques have been used to deliver transperineal prostate brachytherapy, 
using Pd-103, I-125 and, more recently, Cs -131(Sommerkamp, et al 1988, Reed, et al, 2007, 
Spadlinger, et al, 2006, Meigooni, et al, 2004, Yue, et al, 2005). These sources are typically 
implanted as individual seeds, or as seeds that are stranded together or held together using 
plastic linking devices (Sommerkamp, et al 1988, Reed, et al, 2007, Spadlinger, et al, 2006). 
Stranded or linked seeds have the advantage that they are less likely to migrate from their 
implant position than individually implanted seeds (Sommerkamp, et al 1988, Reed, et al, 
2007, Spadlinger, et al, 2006). Additionally, implants can be either performed via pre-plans, 
in which a planning ultrasound is performed before the surgery, or with intra-operative 
planning (Matzkin, et al, 2003). 
While a linear brachytherapy source in the form of a coiled 103Pd wire was developed, it 
never became available clinically (Meigooni, et al, 2004). The possibility of using a 
continuous linear source led to the consideration of continuously linked seeds in an implant 
rather than the normal use of seeds separated by spacers. The elimination of spacers would 
allow the same number of seeds to be implanted into the prostate with fewer needles. The 
number of needles used in prostate seed implants has been shown to be correlated with 
acute urinary morbidity after seed implantation. (Eapen, et al, 2004, Ohashi, et al, 2006, 
Bucci, et al, 2002, Lee, et al, 2000, Buskirk, et al, 2004, Bottomley, et al, 2007, Keyer, et al, 
2009, Thomas, et al, 2008). Also, the use of fewer needles should cause less trauma to the 
base of the penis, which may help preserve erectile function (Macdonald, et al, 2005, 
Steggerda, et al, 2010).  
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In eliminating spacers between seeds and reducing the number of needles used for 
implantation, it is important that implant quality is not adversely affected. In this study a 
comparison of post-implant dosimetry in patients treated with conventional linked seed 
implants with spacers (+S) to those treated with a novel technique using linked seed 
implants without spacers between the sources (-S) is performed, as well as a comparison of 
the numbers of needles used for each technique.   
2. Strategy to provide monotherapy palladium-103 implants 
The day 0 post implant dosimetry of 101 consecutive patients who received monotherapy 
Palladium-103 implants was retrospectively reviewed. To avoid selection bias the dosimetric 
data from the final 48 +S, and the first 53 -S patients implanted at our institution were 
analyzed. Prior to this study the implant team had performed more than 800 permanent seed 
prostate implants. The ultrasound images taken at the time of the implant in the operating 
room were transferred to the Variseed TM 7.0 software (Varian, Palo Alto, CA). The radiation 
oncologist then developed a treatment plan to deliver a minimum dose of 125 Gy to the 
prostate with a margin of approximately 5 mm anteriorly and laterally, with a smaller 
posterior margin. All patients were implanted using Bard® BrachyStar® seed implant needles 
containing Theragenics® TheraSeed® palladium-103 sources with an average activity of 2.08 
(Range 1.78-2.31) linked with 0.5 mm seed-to-seed SourceLink™ links or 5 mm SourceLink™ 
spacer links, for the -S and +S cohorts respectively, assembled using a SourceLink™ loader. A 
photograph of the linked seeds without the use of spacers is shown in Figure 1, along with a 
schematic diagram of the linked seeds. All patients had a CT scan for post-implant dosimetry 
within 3 hours following the implant. A Foley catheter was in place during the implant 
procedure, and for the post-implant CT scan. A single radiation oncologist planned, treated, 
and performed post-implant contouring of the prostate.  
 
Fig. 1. Photograph (a) and schematic diagram (b) of a strand of linked seeds. 
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Forty-eight patients (+S) were implanted using linked seeds with a single spacer between 
each seed, except at the apex of the gland where 2 seeds were frequently placed without a 
spacer between them. Another 53 patients (-S) had implants in which all seeds were linked 
without spacers between them. Other than use of spacers, both groups of patients were 
planned and implanted in the same manner. 
Using the Variseed TM 7.0 software (Varian, Palo Alto, CA), dose-volume histograms were 
compiled for each patient and were used to determine the prostate V800, V400, V350, V300, 
V250, V200, V150, V100, V90 and V80, prostate D100, D90 and D80, and urethral D90, D30, 
and D10 using a point source approximation (Pd-103 M200 Corrected [NIST 99]). 
The automatic seed finder was utilized to locate the Pd-103 seeds in the CT data sets, which 
were subsequently reviewed by the physician to assure that location of the seeds was 
correctly identified and that the number of seeds identified matched the number that was 
implanted. The post implant prostatic D90 is defined as the dose covering 90% of the 
prostate volume. The V100 is defined as the volume of the prostate that receives 100% of 
prescribed dose. The post implant dosimetric analysis was performed according to the 
American Brachytherapy Society’s guidelines for permanent prostate brachytherapy (Nag, 
et al, 2000).  
Statistical Methods: The dosimetric variables, as well as the average number of needles and 
seeds used for each group, were statistically compared using Student’s t-tests to determine if 
there were significant differences between the two types of implants. Demographic and 
clinical factors including prostate volume, patient age, clinical stage, pre-implant PSA, and 
Gleason score were evaluated using Student’s t-tests or chi-square tests of association to 
determine whether the two cohorts were similar. All statistical analyses were performed 
using SAS® Version 9.1 (Cary, NC, USA). All tests were performed using a Type I error rate 
of 0.05. 
3.1 Demographics, disease and treatment characteristics 
The clinical characteristics of our study cohorts are presented in Table 1. Statistical analysis 
showed no significant differences between age, mean pre-implant PSA, Gleason’s score or 
pre-implant prostate volume. The prostate volumes were similar for the two groups (39.3 
cm3 for +S and 36.7 cm3 for -S).  
3.2 Number of needles and seeds 
Comparison between the two cohorts (Table 1) showed that an average of 100.8 seeds and 
23.1 needles were used for implants without spacers, while an average of 94 seeds and 31.5 
needles were required when implanting with spacers. This difference in numbers of needles 
used was statistically significant (p<0.001), but there was no statistically significant 
difference in the number of seeds in the two types of implants (p=0.16).  
3.3 Dosimetric parameters and outcomes 
Detailed dosimetric analysis results are found in Table 2. The mean prostatic D90 for the +S 
cohort was 99.2 Gy, slightly higher than the 95.5 Gy calculated for the -S cohort, but this 
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difference was not statistically significant (p=0.22). The prostate D80 and D100 values were 
also not significantly different between the two cohorts (Figure 2).  
 
Variable +S* -S† p-Value 
Mean Age (years) 66.2 63.5 0.068 
Mean Preimplant PSA‡ (ng/ml) 6.3 6.0 0.93 
Mean Combined Gleason Score 6.2 6.2 0.88 
T-stage, number (%) 
T1c 
T2a 
T2b 
T2c 
 
38 (79.2) 
9 (18.8) 
0 (0) 
1 (2.1) 
 
45 (84.9) 
7 (13.2) 
0(0) 
1 (1.9) 
 
 
0.45 
Mean Prostate Volume (cm3) 39.3 36.7 0.31 
Mean Urethral Volume (cm3) 1.4 1.4 0.97 
Mean Number of Needles 31.5 23.1 <0.001 
Mean number of Seeds 94 100.8 0.16 
Mean number of seeds per needle 3.0 4.4 <0.001 
*+S: Patients receiving implantation with spacers. † -S: Patients receiving implantation with linked seed 
implants without spacers between the sources.  ‡PSA = Prostate Specific Antigen.  
Table 1. Demographic and Clinical Cohort Comparison 
 
Dosimetric Variable +S* -S† p-Value 
Prostate, Mean V800(%) 2.4 2.0 0.029 
Prostate, Mean V400(%) 7.1 6.1 0.005 
Prostate, Mean V200(%) 30.6 27.4 0.058 
Prostate, Mean V150(%) 56.3 52.0 0.077 
Prostate, Mean V100(%) 88.1 85.8 0.19 
Prostate, Mean V90(%) 92.2 90.8 0.28 
Prostate, Mean  D100 (Gy) 44.2 45.4 0.63 
Prostate, Mean D90 (Gy) 99.2 95.5 0.22 
Prostate, Mean D80 (Gy) 116.8 112.3 0.15 
Urethra, Mean V100(%) 41.5 51.5 0.038 
Urethra, Mean V100(%) 121.4 119.7 0.70 
Urethra, Mean V100(%) 139.8 137.6 0.70 
*+S = Patients receiving implantation with spacers between the linked sources.  
† -S = Patients receiving implantation with linked seed implants without spacers 
Table 2. Summary of Dosimetric Analysis 
The urethral D90 was significantly higher (p=0.038) in the group without spacers (51.5 Gy) 
compared to the group with spacers (41.5 Gy) shown in Figure 3.  
The mean V100 for the -S cohort was 85.8% compared to a mean V100 of 88.1% for the +S 
cohort (p= 0.19). Also there were no statistically significant differences in the mean V80 and 
V90 for each of the cohorts. 
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Fig. 2. Mean Prostate dose for the implants performed with (+S) and without (-S) spacers. 
 
Fig. 3. Mean urethral dose for the implants performed with (+S) and without (-S) spacers. 
The mean V150, V200,V250, V300, V350, V400 and V800 were also calculated and compared 
between the two cohorts, as shown in Figure 4.  
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Fig. 4. Mean Prostate V150-800 for the implants performed with (+S) and without (-S) 
spacers. 
The mean V150 and V200 for the +S were 56.3% and 30.6% of the prostatic volume 
respectively compared to 52.0% and 27.4% of the prostatic volume respectively for the -S 
group. While the differences in the V150 and V200 are surprisingly higher for the +S as 
compared to the -S cohort these differences failed to be statistically significant but were 
trending (p=0.077 and p=0.058 respectively). This trend of higher V values for the +S cohort 
as compared to the -S group continued. The +S mean V250, V300,V350, V400 and V800 are 
17.9%, 12% , 9.1%, 7.1% and 2.4% of the total prostatic volume respectively and are elevated 
compared to these same values for the -S cohort which are, 15.8%, 10.5%, 7.8%, 6.1% and 2% 
of the total prostatic volume respectively (Figure 3). Statistical analysis demonstrated that 
for each of these measurements that the percentage of volume of the prostate receiving 2.5-8 
times the prescribed dose was significantly higher for the +S cohort. A plot of total 
implanted activity as a function of prostate volume for both the +S and –S cohorts is shown 
in Figure 5. This plot shows that the total implanted activity is the same for implants using 
spacers or not, which confirms the dosimetric data. 
4. Review of implants 
The development of the RadioCoilTM linear 103Pd source prompted studying the use of Pd-
103 seeds linked in a continuous linear fashion, in order to decrease the number of implant 
needles and possibly decrease toxicity. This study was not intended to assess toxicity, but 
rather to compare post-implant dosimetry for patients receiving implants using 
conventional spacers with those whose implants used seeds continuously linked without 
spacers. Interestingly there are few dosimetric differences between the two groups.  
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Fig. 5. Total Implanted activity as a function of prostate volume for the two arms of the 
study 
Our data show a significant decrease in the volume of prostate tissue receiving greater that 
100% of the prescribed dose (V250-V800) in the -S patients. This result was not expected. 
One of the main concerns about using continuous sources is the creation of “hot spots”. 
However, our data show that this is not the case. All of the mean V values calculated for the 
-S cohort were less than those of the +S cohort.  
The elimination of spacers between seeds allowed a significant decrease in the total number 
of needles used during prostate implants. This may prove to be clinically significant since 
needle trauma likely plays a role in post implant morbidity. Acute urinary toxicity is the 
predominant side effect of prostate brachytherapy and acute urinary retention (AUR) is a 
well recognized and described early toxicity (Mallick, et al, 2003). Most obstructive 
symptoms occur quickly after the implant procedure before the dose deposited by the 
sources to the surrounding tissue can reach a significant level (Bucci, et al, 2009). This 
suggests that prostatic trauma from the procedure is the predominant factor in obstructive 
urinary symptoms. Studies have been conducted to try to identify factors that predict post 
implant AUR.  
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There have been many studies reporting on AUR rates after prostate brachytherapy, with 
the number of needles used, the number of seeds implanted, hormonal manipulation, pre-
implant prostate volume, the level of post-implant prostatic edema, and diabetes all linked 
to increased AUR rates(Ohashi, et al 2006, Bucci, et al, 2002, Lee, et al 2000, Buskirk, et al, 
2004, Bottomley, et al, 2007, Keyer, et al, 2009, Thomas, et al 2008, Macdonald, et al, 2005). 
While there are no large randomized controlled trials, many of the references cited provide 
evidence that prostate gland trauma caused by needle insertion during brachytherapy 
implant plays some role in the development of post-operative AUR. Therefore, decreasing 
the number of needles required to perform quality implants could play a role in decreasing 
post implant AUR. It remains to be seen if reduced AUR is seen in patients undergoing -S 
compared to +S. It is important to note that decreasing the number of needles used for 
prostate implantation can predispose to unwanted hot or cold regions if the needle position 
is not placed correctly. Thus, this technique should only be undertaken by experienced 
brachytherapy teams. 
The use of a retrospective, rather than a randomized, method to study possible dosimetric 
differences between the +S and –S arms of the study could have led to errors associated with 
all non-randomized trials. The use of Day 30, rather than or in addition to Day 0 CT scans, 
may have shown either differences in the data not present in the Day 0 or allowed the 
tracking of the dosimetric parameters as a function of time. 
5. Conclusion 
This study was designed as an analysis of prostate seed implants comparing the 
dosimetric characteristics of implants performed both with (+S) or without (-S) the use of 
spacers between the seeds. The results presented in this study show that +S and -S 
implants were dosimetrically similar, with a significant reduction in the number of 
needles required for the treatments without the use spacers (-S). Analysis of the total 
implanted activity as a function of prostate volume are essentially identical between the 
two arms of the study, which helps to clarify the similarity in dosimetric characteristics of 
the –S and +S implants. Studies have shown that the number of needles used for 
brachytherapy correlates to AUR; therefore, we expect a decreased rate of AUR with this 
technique. It remains to be evaluated what significance implants with -S has on urinary 
quality of life.  
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